The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer
Official Title: Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT]
Study ID: NCT00553345
Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of selenium and vitamin E may stop cancer from growing or coming back. PURPOSE: This randomized phase III trial is studying giving selenium together with vitamin E to see how well it works compared with a placebo in preventing cancer progression and recurrence in patients with early-stage bladder cancer.
Detailed Description: OBJECTIVES: * To investigate whether selenium and/or vitamin E (α-tocopherol) supplementation reduces the risk of recurrence and progression. OUTLINE: This is a multicenter study. Patients are stratified by recurrence risk group (high vs intermediate) and treatment center and randomized to 1 of 4 treatment arms. * Arm I: Patients receive oral selenium tablet and oral vitamin E capsule once daily. * Arm II: Patients receive oral selenium tablet and oral placebo capsule once daily. * Arm III: Patients receive oral placebo tablet and oral vitamin E capsule once daily. * Arm IV: Patients receive oral placebo tablet and oral placebo capsule once daily. In all arms, treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity. Quality of life is assessed every 6 months for 5 years. Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Birmingham, Birmingham, England, United Kingdom
Name: Maurice Zeegers
Affiliation: University of Birmingham
Role: STUDY_CHAIR